Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
16.20
+0.03 (0.19%)
At close: Nov 7, 2025, 4:00 PM EST
15.53
-0.67 (-4.15%)
After-hours: Nov 7, 2025, 5:10 PM EST
Keros Therapeutics Revenue
Keros Therapeutics had revenue of $14.26M in the quarter ending September 30, 2025, with 3,575.77% growth. This brings the company's revenue in the last twelve months to $246.72M, up 37,798.31% year-over-year. In the year 2024, Keros Therapeutics had annual revenue of $3.55M with 2,250.99% growth.
Revenue (ttm)
$246.72M
Revenue Growth
+37,798.31%
P/S Ratio
2.66
Revenue / Employee
$1,459,870
Employees
169
Market Cap
493.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.55M | 3.40M | 2,250.99% |
| Dec 31, 2023 | 151.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 20.10M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
KROS News
- 3 days ago - Keros Therapeutics Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 19 days ago - Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares - GlobeNewsWire
- 24 days ago - Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital - GlobeNewsWire
- 2 months ago - Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting - GlobeNewsWire
- 2 months ago - Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - GlobeNewsWire
- 2 months ago - ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment - PRNewsWire
- 2 months ago - Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy - GlobeNewsWire
- 3 months ago - Keros to Exclusively Prioritize the Clinical Advancement of KER-065 - GlobeNewsWire